Form 4 for RCEL AVITA Medical, Inc.

Accepted 2025-06-05 00:00:00 ET · period of report 2025-06-04 · accession 0000950170-25-082422 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-06-05	2025-01-21	RCEL	Crowe Suzanne	Dir	A - Grant	—	+10.0K	46.9K	+27%	—
D	2025-06-05	2025-01-21	RCEL	Crowe Suzanne	Dir	A - Grant	$0.00	+4,295	4,295	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-01-21	A	A	10,022	—	46,934	D	—	—	(F1) Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 21, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025. (F2) Includes unvested RSUs. (F3) Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.
2	Derivative	Stock Options (Right to Buy)	2025-01-21	A	A	4,295	$0.00	4,295	D	$8.73 · 2026-01-21 to 2035-01-21	4,295 Common Stock	(F4) On January 6, 2025, the Board of Directors approved a grant of 4,295 options to acquire 4,295 shares of Common Stock to each of its non-executive directors, with a grant date of January 21, 2025 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $8.73. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 4, 2025.